|
Biosimilar drugs’ global revenues “to hit $2.44B this year”
PharmaTimes From 2014, many companies will be trying to launch mAb biosimilar products, and the majority will be targeting Roche’s Rituxan (rituximab) and Herceptin (trastuzumab), and Johnson & Johnson/Merck & Co/Mitsubishi Tanabe’s Remicade (inflximab) for … |
HealioImmunotherapy plus high-dose chemotherapy effective in primary CNS lymphomaHealioThe multicenter study included 44 patients with newly diagnosed primary central nervous system lymphoma treated with methotrexate, temozolomide and rituximab inducti…
Test Can Easily ID Broadly Neutralizing Antibodies Against HIVAIDSmeds.com HIV/AIDS Treatment NewsScientists sponsored by the National Institutes of Health (NIH) have developed a powerful new assay that can screen blood for broadly neutralizing antibod…
|
Lilly Scraps Oncology Candidate – Analyst Blog – NASDAQ.com
NASDAQ … the phase III PRELUDE study showed that enzastaurin failed to show a statistically significant improvement in disease-free survival compared to placebo in patients at high risk of relapse following treatment with Roche’s ( RHHBY ) Rituxan … |
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in …PharmiWeb.com (press release)The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse …
|
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
Seeking Alpha OB) Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan (rituximab), and Zelboraf (vemurafenib). This article is the first of three articles about Array. This article looks at Array’s promising collaborations with some of the biggest names in the … |
Asian Scientist MagazineHuahai, Oncobiologics Partner On Biosimilar Monoclonal AntibodiesAsian Scientist MagazineHuahai, Oncobiologics Partner On Biosimilar Monoclonal Antibodies. Huahai Oncobiologics Partner On Biosimilar Monoclonal Antibodies. Tech &…
Clinical Notes: Cause of Death Often False – MedPage TodayMedPage TodayEnzastaurin is a serine-threonine kinase inhibitor that inhibits tumor angiogenesis by targeting protein kinase C-beta and the PI3K/AKT pathway. The lymphoma trial had enrolled pati…
|
MDS Symposium 2013 Update – Day Two, Morning Sessions
The MDS Beacon Common immunosuppressive agents used in the treatment of MDS are anti-thymocyte globulin (ATG) and cyclosporine (Sandimmune). Dr. Passweg started his presentation by pointing out that immunosuppressive therapy is standard in the treatment of … |
|
ImmunoGen’s Management Presents at Credit Suisse Antibody Day Conference …
Seeking Alpha CD-37 is primarily found on NHL and also it’s generally found in the same place of CD20 as which is a supposed target for rituximab. Significant disease, one of the interesting aspects of the design of CD37 or IMGN529 is the fact that we have very … |